Work

Optimizing Donor Choice and GVHD Prophylaxis in Allogeneic Hematopoietic Cell Transplantation

Year: 2021

Type: review

Abstract: Key ObjectiveOutline the design and development of approaches to select the best donor and limit the morbidity of graft-versus-host disease (GVHD) after allogeneic hematopoietic cell transplantation (HCT).Knowledge Generated Balancing human leukocyte antigen matching, graft source, and other donor characteristics can assure engraftment, limit GVHD and promote immune reconstitution; all to improve HCT outcomes.Relevance Continuing research into novel genetic features in donors, better GVHD prophylaxis, and unique GVHD treatments will make HCT safer, less toxic, and less costly.

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.20.01771

Authors: Shernan G. Holtan, Jurjen Versluis, Daniel J. Weisdorf, Jan J. Cornelissen

Institutions: University of Minnesota, Erasmus MC, Erasmus MC Cancer Institute

Language: English

Topic: Hematopoietic Stem Cell Transplantation

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funder: Bristol-Myers Squibb